Diabetes at midlife influences risk of diabetes and cognitive decline in later years
the ONA take:
Substantial cognitive decline is associated with diabetes, prediabetes, and poor glucose control. The potential decline begins at midlife, when poor dietary habits and a lack of exercise leads to diabetes at approximately age 50 years.
These are the findings of a study by researchers at Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland. The researchers analyzed data from the Atherosclerosis Risk in Communities Study involving 15,792 middle-age adults who had been followed since 1987.
The participants’ health was assessed approximately every 3 years, and a fifth assessment was conducted between 2011 and 2013. Three of the assessments included analysis of participants’ cognitive function. The rate of cognitive decline among the study participants was compared with age-related cognitive decline in the general population.
The researchers found that study participants with poorly controlled diabetes were 19% more likely to experience cognitive decline, or approximately 5 years sooner than healthy persons of the same age. The researchers conclude that to have a healthy brain at age 70 years, people need to eat right and exercise in their 50s.
Substantial cognitive decline is associated with diabetes, prediabetes, and poor glucose control.
- Prehabilitation Program Improves Preoperative Fitness in Patients With Colorectal Cancer
- Acupuncture Improves Postoperative Symptoms in Women Undergoing Surgery for Breast Cancer
- Combination of Gemcitabine and New CHK1 Inhibitor Is Effective in Soft Tissue Sarcomas
- Alcohol Consumption, Particularly White Wine, Associated With Increased Risk of Melanoma
- In HER2+ Breast Cancer, Higher TIL Levels Associated With Improved OS
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness
- New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent Metastases
- Netupitant/Palonosetron Efficacious for Prevention of N/V in Patients Receiving MEC or HEC
- Costs, Complications Higher for Women Who Undergo Second Surgery After BCS
- Omitting RT in Certain Older Women With Early Breast Cancer is Safe
- Fluorescent Nanoparticles Represent Novel Detection Method of HER2 Expression
- Assessment of Stromal Features in DCIS Requires Robustness
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|